Want to see SER full AI Analyst Report?
SER Stock Chart & Stats
$2.05
<$0.01(0.21%)
At close: 4:00 PM EST
$2.05
<$0.01(0.21%)
Day’s Range― - ―
52-Week Range$1.22 - $7.92
Previous CloseN/A
Volume4.86K
Average Volume (3M)24.47K
Market Cap
$27.15M
Enterprise Value$93.00K
Total Cash (Recent Filing)$24.53M
Total Debt (Recent Filing)$3.17M
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Aug 07, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding14,997,505
10 Day Avg. Volume14,098
30 Day Avg. Volume24,472
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.72
Enterprise Value/Gross Profit0.97
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside436.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Capital StructureSerina’s current balance sheet shows very low financial leverage and a meaningful asset base, providing durable financing flexibility for development-stage R&D. This conservatism supports runway extensions, partner deals, or non-dilutive options versus highly leveraged peers, improving resilience over months.
Platform Drug-delivery FranchiseThe polymer-conjugate platform targets long-acting and controlled-release formulations for CNS and chronic indications, a structural industry need. Platform potential increases partnership and licensing optionality, diversifies future revenue sources, and enhances long-term commercial scalability beyond single-product risk.
Governance And Leadership AlignmentRecent shareholder approvals and board/compensation ratifications signal investor backing and clearer governance. That alignment supports quicker decision-making, capital-raising capability and incentive structures that can retain technical talent and advance programs, strengthening execution capacity over time.
Bears Say
Minimal Revenue BaseRevenue remains negligible versus operating scale, leaving Serina heavily reliant on external funding. With product commercialization still distant, the minimal revenue base limits ability to absorb R&D spending, weakens operating leverage, and makes multi-quarter sustainability contingent on financing events.
Large And Ongoing Cash BurnConsistent negative operating and free cash flow indicate the business is not self-funding and consumes capital at a pace that requires periodic raises. Persistent burn constrains strategic optionality, increases execution risk if markets tighten, and pressures management to secure dilutive financing within months.
Dilution Risk From Expanded Share CapacityThe large increase in authorized shares and incentive pool materially expands the company’s capacity to issue equity. While useful for funding and incentives, this creates a structural dilution pathway that can dilute per-share economics and returns for existing holders as future financing or deal-related issuances occur.
Serina Therapeutics News
SER FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was $1.22 and its highest was $7.92 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is $27.15M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 38 days.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on May 14, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.44 by -$0.14.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.46.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 14,997,505 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.44. Following the earnings report the stock price went down -4.651%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in SER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
SER Stock 12 Month Forecast
Average Price Target
$11.00
▲(436.59% Upside)
Technical Analysis
Outlook Therapeutics
―
Skye Bioscience
―
Celularity
―
Barinthus Biotherapeutics
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
59.00% Insiders
1.32% Mutual Funds
6.94% Other Institutional Investors
31.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---